Clinical cardiac tolerability of trastuzumab

Journal of Clinical Oncology

Volumn 22, Issue 2, 2004, Pages 322-329

  Perez, Edith A ^a   Rodeheffer, Richard ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; BREAST CANCER; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DRUG SAFETY; DRUG TOLERABILITY; HEART DISEASE; HEART EJECTION FRACTION; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; SYMPTOM; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG INTERACTION; FEMALE; HEART STROKE VOLUME; MONITORING; REVIEW;

ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG INTERACTIONS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MONITORING, PHYSIOLOGIC; RISK FACTORS; STROKE VOLUME;

EID: 1342311012     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.01.120     Document Type: Article

References (38)

1. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
2. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989
3. Coussens L, Yang-Feng TL, Liao YC, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1139, 1985
4. Hudziak RM, Lewis GD, Winget M, et al: P185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9:1165-1172, 1989
5. Baselga J, Norton L, Albanell J. et al: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825-2831, 1998
6. Lewis GD, Figari I, Fendly B, et al: Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 37:255-263, 1993
7. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
8. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
9. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
10. Herceptin [package insert]. South San Francisco, CA, Genentech Inc. 2003
11. Seidman A, Hudis C, Pierri MK, et al: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215-1221, 2002
12. Criteria Committee of the NYHA. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels (ed 7). Boston, MA, Little, Brown, 1973
13. Tripathy D, Seidman A, Hudis C, et al: Effect of cardiac dysfunction on treatment outcome in the Herceptin pivotal trial. Breast Cancer Res Treat 69:75, 2001 (abstr 525)
14. Burstein HJ, Kuter I, Campos SM, et al: Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19:2722-2730, 2001
15. Seidman AD, Fornier MN, Esteva FJ, et al: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19:2587-2595, 2001
16. Esteva FJ, Valero V, Booser D, et al: Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20:1800-1808, 2002
17. Rastogi P, Brufsky AM, Landsittel D, et al: Differences in cardiac ejection fractions for breast cancer patients treated with doxorubicin or trastuzumab. Proc Am Soc Clin Oncol 21:66a, 2002 (abstr 262)
18. Tan-Chiu E, Piccart M: Moving forward: Herceptin in the adjuvant setting. Oncology 63: 57-63, 2002 (suppl 1)
19. 18A. Geyer CE Jr, Bryant J, Romond E, et al: Cardiac safety analysts of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of Adriamycin and cyclophosphamide (AC) followed by Taxol to that of AC plus Herceptin in patients (Pts) with operable, node-positive (N+), HER-2 overexpressing breast cancer (HER2 + BC). Presented at the 26th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 2003
20. Hortobagyi GN, Perez EA: Integration of trastuzumab into adjuvant systemic therapy of breast cancer: Ongoing and planned clinical trials. Semin Oncol 28:41-46, 2001
21. Abbas Abidi SM, Howard EW, Dmytryk JJ, et al: Differential influence of antiestrogens on the in vitro release of gelatinases (type IV collagenases) by invasive and non-invasive breast cancer cells. Clin Exp Metastasis 15:432-439, 1997
22. Perez EA, Suman VJ, Davidson NE, et al: Effect of doxorubicin plus cyclophosphamide (AC) on left ventricular ejection fraction (LVEF) in the NCCTG N9831 Intergroup Adjuvant Trial. Proc Am Soc Clin Oncol 22:19, 2003 (abstr 75)
23. Sledge GW, O'Neill A, Thor AD, et al: Pilot trial of paclitaxel-Herceptin adjuvant therapy for early stage breast cancer (E2198), 24th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, 2001
24. Harris KA, Washington CB, Lieberman G. et al: A population pharmacokinetic (PK) model for trastuzumab (Herceptin) and implications for clinical dosing. Proc Am Soc Clin Oncol 21:123a, 2002 (abstr 488)
25. Carey LA, Dees EC, Sawyer L, et al: Cardiotoxicity of trastuzumab (Herceptin, H) given with weekly taxol (T) immediately following 4AC as initial therapy for primary breast cancer. Proc Am Soc Clin Oncol 21:64a, 2002 (abstr 253)
26. Theodoulou M, Campos SM, Batist G, et al: TLC D99 (D, Myocet) and herceptin (H) is safe in advanced breast cancer (ABC): Final cardiac safety and efficacy analysis. Proc Am Soc Clin Oncol 21;55a, 2002 (abstr 216)
27. Eidtmann H, Thomssen CH, Untch M, et al: Herceptin (R) in combination with epirubicin plus cyclophosphamide: Interim results on cardiac safety and efficacy in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 21:60a, 2002 (abstr 236)
28. Thomssen CH, Eidtmann H, Untch M, et al: Cardiac safety of epirubicin/cyclophosphamide (EC) alone and in combination with Herceptin in women with metastatic breast cancer (MBC). Breast Cancer Res Treat 76:111, 2002 (abstr 430)
29. Gianni L, Albanell J, Eiermann W, et al: Feasibility, pharmacology, and antitumor activity of Herceptin (H) with doxorubicin and Taxol followed by weekly Taxol (AT&T) in women with HER2-positive advanced breast cancer (ABC). Proc Am Soc Clin Oncol 20:44a, 2001 (abstr 174)
30. ECOG protocols active as of 04/25/03: http://www.ecog.org/active_reports/ Breast.html
31. Wolff AC, Bonetti M, Sparano JA, et al: Cardiac safety of trastuzumab (H) in combination with pegylated liposomal doxorubicin (D) and docetaxel (T) in HER2-positive metastatic breast cancer (MBC): preliminary results of the Eastern Cooperative Oncology Group trial E3198. Proc Am Soc Clin Oncol 22:18, 2003 (abstr 70)
32. Venturini M, Nicoletto O, Bighin C, et al: A multicenter phase II study of trastuzumab with epirubicin and docetaxel as a first line treatment in metastatic breast cancer. Proc Am Soc Clin Oncol 22:34, 2003 (abstr 134)
33. Crone SA, Zhao YY, Fan L, et al: ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8:459-465, 2002
34. Chien KR: Stress pathways and heart failure. Cell 98:555-558, 1999
35. Lee KF, Simon H, Chen H, et al: Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378:394-398, 1995
36. Erickson SL, O'Shea KS, Ghaboosi N. et al: ErbB3 is required for normal cerebellar and cardiac development: A comparison with ErbB2-and heregulin-deficient mice. Development 124: 4999-5011, 1997
37. Ewer MS, Vooletich M, Valero V, et al: Trastuzumab (Herceptin) cardiotoxicity: Clinical course and cardiac biopsy correlations. Proc Am Soc Clin Oncol 21:123a, 2002 (abstr 489)
38. Gharib MI, Burnett AK: Chemotherapy-induced cardiotoxicity: Current practice and prospects of prophylaxis. Eur J Heart Fail 4:235-242, 2002